Teva Respiratory
Vienna
United States
Tel: 888-482-9522
10 articles about Teva Respiratory
-
Teva, Amazon Web Services and Onica Announce Collaboration to Support Teva’s Digihaler® Portfolio
10/21/2020
Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd. announced that the company is collaborating with Amazon Web Services, Inc. and Onica, a Rackspace Technology company, to build and host its Digital Health Platform.
-
Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD
7/13/2020
Teva Announces Availability of ProAir ® Digihaler ® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD - First and Only Digital Rescue Inhaler with Built-In Sensors Now Available By Prescription to Patients in the U.S. - Companion App Provides Objective Inhaler Event Data, Including Peak Inspiratory Flow. This data may be used to facilitate Health Care Provider-Patient Communication
-
Teva Announces FDA Approval of ArmonAir® Digihaler™ (fluticasone propionate) Inhalation Powder
2/24/2020
Feb. 24, 2020 13:00 UTC Teva Announces FDA Approval of ArmonAir ® Digihaler™ (fluticasone propionate) Inhalation Powder Teva’s Digital Inhaler Portfolio Now Includes Products from Three of the Most Commonly Prescribed Classes of Asthma Treatments TEL AVIV & PARSIPPANY, N.J.--( BUSINESS WIRE )-- Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved Arm
-
Heartbeat Ideas and Teva Respiratory Beautiful Tree Online Campaign Wins “Best in Category” Internet Advertising Competition and DTC National Ad Awards
7/16/2013
-
Teva Respiratory Release: ProAir® HFA (Albuterol Sulfate) With Dose Counter Now Available to Patients
1/3/2013
-
Teva Respiratory Receives FDA Approval for ProAir® HFA (albuterol sulfate) With Dose Counter
3/8/2012
-
Teva Respiratory Provides Resources for Patients Impacted by PRIMATENE(R) MIST Phase-Out
10/3/2011
-
Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis
7/28/2010
-
Teva Respiratory: Landmark Survey Reveals Respiratory Symptoms During Exercise Contribute to Poor Quality of Life in the U.S
3/1/2010
-
Teva Respiratory: Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options
9/16/2009